Guangzhou Baiyunshan Pharmaceutical Holdings (00874) affiliate plans to participate in the establishment of Guangzhou Pharmaceutical Guangkai Fund and Guangzhou Pharmaceutical Liwan Fund.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that on December 22, 2025, the board of directors approved the establishment of Guangzhou Baiyunshan Phase II Fund, Guangzhou Baiyunshan Capital, and Guangzhou Kai Fund to establish a partnership agreement. According to this agreement, Guangzhou Baiyunshan Phase II Fund, Guangzhou Baiyunshan Capital, and Guangzhou Kai Fund each contributed RMB 97.5 million, RMB 2.5 million, and RMB 100 million to participate in the establishment of the Guangzhou Baiyunshan Kai Fund. On the same day, the board of directors approved Guangzhou Baiyunshan Phase II Fund to establish Guangzhou Baiyunshan Liwan Fund in partnership with Guangzhou Baiyunshan Capital, Angel Mother Fund, and Liwan Investment Fund. According to this agreement, Guangzhou Baiyunshan Phase II Fund, Guangzhou Baiyunshan Capital, Angel Mother Fund, and Liwan Investment Fund each contributed RMB 99.5 million, RMB 3.5 million, RMB 98.5 million, and RMB 98.5 million to participate in the establishment of the Guangzhou Baiyunshan Liwan Fund. This investment aligns with the investment direction of Guangzhou Baiyunshan Phase II Fund, which will help expand the fund's investment scale, diversify investment risks, accelerate investment pace, and improve investment efficiency. It will strengthen the company's layout in the forefront of biomedicine such as innovative drugs, modern traditional Chinese medicine, and high-end medical devices. By investing early, investing in small companies, and investing in the future, the company aims to proactively invest in high-quality enterprises, nurture potential companies, accelerate technological upgrades and value chain extension, and drive the company's transition from a traditional business model to a model driven by technological innovation, laying a solid foundation for high-quality development.